Great news for the Orlando region: global pharmaceutical giant Novartis has selected Winter Park as the site for a new radioligand therapy manufacturing facility, according to the Orlando Economic Partnership.
The announcement is part of a broader wave of economic momentum for the area. The Orlando Economic Partnership also reported that Orlando is leading the entire nation in job growth, population growth, and GDP growth — a rare “triple crown” of economic achievement that signals strong opportunity for residents and businesses alike.
The Novartis facility represents a significant expansion of the life sciences sector in Central Florida, bringing high-quality manufacturing jobs to the Winter Park community. Radioligand therapy is an advanced area of cancer treatment, meaning the new facility will not only create local employment but also contribute to cutting-edge medical innovation.
Together, these milestones paint an encouraging picture of a region on the rise — attracting world-class investment while continuing to grow its workforce and economy at a pace unmatched anywhere else in the country.
Sources: Orlando Economic Partnership, Orlando Economic Partnership
